1-1 of 1
Keywords: anthracyclines
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles

In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline

Zuzana Pokorna, Eduard Jirkovsky, Marketa Hlavackova, Hana Jansova, Anna Jirkovska, Olga Lencova-Popelova, Petra Brazdova, Jan Kubes, Dita Sotakova-Kasparova, Yvona Mazurova, Michaela Adamcova, Lucie Vostatkova, Kristyna Holzerova, Frantisek Kolar, Tomas Simunek, Martin Sterba
Journal: Clinical Science
Clin Sci (Lond) (2019) 133 (16): 1827–1844.
https://doi.org/10.1042/CS20190139
Published: 27 August 2019
... inhibitors (PIs) are modern targeted anticancer drugs, they have been associated with a certain risk of cardiotoxicity and heart failure (HF). Recently, PIs have been combined with anthracyclines (ANTs) to further boost their anticancer efficacy. However, this raised concerns regarding cardiac safety, which...
View article titled, In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with <span class="search-highlight">anthracycline</span>
Open the PDF for In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with <span class="search-highlight">anthracycline</span> in another window
Includes: Supplementary data